Clinical and pathological features, such as the size of the tumor, tumor grade, rate of lymph node metastasis, patient age, patient morbidity (5), and various biomarkers (e.g., ER, Ki-67, PR, as well as HER-2) (6, 7) are used to predict breast cancer prognosis. This evidence concerns the gene ERBB2 and neoplasm.